On December 11, 2019 Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, reported that Dr. Marnix Bosch, Chief Technical Officer of NW Bio, is presenting at 11:40 a.m. today at the inaugural Glioblastoma (GBM) Drug Development Summit being held at the Westin Boston Waterfront Hotel in Boston, Massachusetts (Press release, Northwest Biotherapeutics, DEC 11, 2019, View Source [SID1234552280]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The title of Dr. Bosch’s presentation is DCVax-L Phase III Clinical Trial: Development of Dendritic Cell Based Immunotherapies for Cancer — Where Are We, and How Did We Get Here.

The conference is not webcasting the presentations. However, Dr. Bosch’s presentation slides will be made available on NW Bio’s website after the conference session. (www.nwbio.com)